CM
About
The CMTA is aggressively pursuing treatments and a cure for all types of CMT. Since launching the Strategy to Accelerate Research (STAR) in 2008, the CMTA has been working with preeminent researchers, clinicians, patients and institutions in the global inherited neuropathy community to capitalize on breakthroughs in genetics. The CMTA has made unprecedented progress toward therapies for virtually almost all types of CMT. Since the inception of STAR, the CMTA has financed more than 100 projects and committed over $23.5 million in research. Thanks to support from our donors, STAR continues to gain momentum and the promise of breakthroughs is imminent.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech edtech
- Location
- Glenolden, US
Contact Information
Find more investors like CMTA
Search Investors